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Endurance training induces the transcriptional coactivator PGC-1a in skeletal muscle, promoting mitochon-
drial biogenesis and skeletal muscle remodeling. In a recent issue of Cell, Ruas et al. (2012) show that resis-
tance training regulates the splicing of a novel isoform of PGC-1a (PGC-1a4), which is sufficient to stimulate
skeletal muscle hypertrophy.Skeletal muscle is central to the health
benefits conferred by exercise. Indeed,
engaging in either of the two general
forms of exercise, aerobic (e.g., long-
distance running and endurance training)
and anaerobic (e.g., weightlifting and
resistance training), promotes remodeling
of skeletal muscle and resistance to
cardiovascular disease, obesity, and
type 2 diabetes (Golbidi et al., 2012).
Thus, intense effort is ongoing to decipher
the molecular pathways that alter skeletal
muscle properties in response to exercise
(Bassel-Duby and Olson, 2006). Skeletal
muscle responds to endurance training
by altering contractile proteins, gener-
ating more mitochondria, and increasing
angiogenesis, whereas resistance
training primarily stimulates growth of
muscle fibers (LeBrasseur et al., 2011;
Yan et al., 2011). Peroxisome prolifera-
tor-activated receptor g (PPARg) coacti-
vator 1a (PGC-1a) was identified adecade
ago as a major transcriptional activator
that regulates the response of skeletal
muscle to endurance exercise (Lin et al.,
2002; Puigserver et al., 2001). PGC-1a is
induced by endurance exercise in both
mice and humans and acts as a transcrip-
tional coregulator to coordinate the
genetic program for fiber-type switching,
mitochondrial biogenesis, and angiogen-
esis (Figure 1). PGC-1a is clearly a central
factor in endurance-dependent muscle
remodeling, and until now it has not
been linked to resistance training adapta-
tions. In a recent issue of Cell, Ruas and
colleagues provide evidence that a novel
isoform of PGC-1a governs hypertrophy
of skeletal muscle in response to resis-
tance training (Ruas et al., 2012).
Previous work identified two indepen-
dent promoters responsible for PGC-1atranscription (Miura et al., 2008; Yoshioka
et al., 2009). Based on this knowledge, the
authors cloned four isoforms using a PCR
strategy specific for the two promoters
and named these species PGC-1a1–
PGC-1a4, where PGC-1a1 is the previ-
ously described PGC-1a and PGC-1a4
is the isoform whose function was
explored. They then asked whether the
different splice variants regulate similar
or different gene sets, using microarray
analysis after infection of cultured primary
skeletal myotubes. While there was
some overlap between the PGC-1a1,
PGC-1a2, and PGC-1a3 regulated genes,
PGC-1a4 induced the most divergent
set of genes. The first clue to under-
standing the physiological function of
PGC-1a4 was the observation that it did
not regulate the same genes as PGC-
1a1, which, as expected, increased
mitochondrial oxidative and angiogenic
genes. Instead, PGC-1a4 regulated
genes in the insulin-like growth factor 1
(IGF-1) and myostatin pathways, which
are well known to regulate hypertrophy
of skeletal muscle. Of note, the a4 iso-
form contains the activation domain
required for PGC-1a1 coactivator activity
yet regulates a completely different set
of genes from the other isoforms. It
will be interesting to understand how
domains in each of these variants confer
specificity for regulation of their particular
gene sets.
Further suggesting a role in muscle
growth, the authors showed PGC-1a4
mRNA was down- and upregulated dur-
ing hindlimb suspension and reloading,
respectively, in mice. PGC-1a4 was
sufficient to induce hypertrophy in vivo
by intramuscular injection of either
naked plasmids or adenovirus encodingCell MetabolismPGC-1a4 and by generation of a
muscle-specific PGC-1a4 transgenic
mouse (myo-PGC-1a4). When assessing
the functionality of a potential hypertro-
phic molecule in skeletal muscle, it is
essential to test it in a setting of muscle
atrophy. Importantly, the authors investi-
gated the response of the myo-PGC-
1a4 transgenic mice to two atrophic
stimuli, hindlimb suspension and cancer
cachexia, via inoculation with Lewis
Lung Carcinoma (LLC) cells. The myo-
PGC-1a4 transgenic mice were resistant
to muscle loss in both settings, but
most strikingly, gastrocnemius weight
was maintained and muscular strength
partially preserved in transgenic mice
after LLC tumor initiation. It is enticing to
speculate that PGC-1a4 may regulate
the size of other tissues in which it is ex-
pressed, such as the heart and brown
adipose tissue. Future work should also
focus on developing antibodies that
recognize the different PGC-1a isoforms,
allowing for definitive analysis of expres-
sion and relative abundance of each
variant at the protein level.
Are there potential clinical implications
related to these findings? That PGC-1a4
is increased modestly (1.5-fold) in hu-
mans after weightlifting may suggest the
PGC-1a4-hypertrophy signaling axis is
functional in human skeletal muscle.
Interestingly, PGC-1a4, along with PGC-
1a, was most dramatically induced in
human skeletal muscle after a combined
exercise protocol where the subjects
participated in both cycling and weight-
lifting. This suggests the most efficient
exercise program to maximize beneficial
muscle remodeling is a combination of en-
durance and resistance training. Further-
more, it indicates some overlap in the17, January 8, 2013 ª2013 Elsevier Inc. 3
Figure 1. Regulation and Function of PGC-1a Variants by Exercise in
Skeletal Muscle
Endurance training activates the proximal promoter of PGC-1a, whereas resis-
tance exercise stimulates the alternative promoter. Proximal promoter usage
and generation of the 1a1 isoform to regulate endurance exercise-dependent
skeletal muscle remodeling has been well established. Ruas and colleagues
(Ruas et al., 2012) have now proposed a function for a PGC-1a isoform (1a4)
during resistance training. Use of the alternative promoter, along with splicing
of a premature stop codon between exons 6 and 7, results in 1a4 isoform
expression and induction of skeletal muscle hypertrophy.
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Previewsexercise-induced regulation
of PGC-1a1 and PGC-1a4.
Thus, one significant avenue
of future investigation will be
to understand how each of
the PGC-1a species is gener-
ated in response to various
exercise stimuli, whether it is
via a different cocktail of
transcription factors and/or
mRNA splicing mechanisms.
Possibly more attractive as a
potential therapy are the
mechanistic insights of
PGC-1a4 function provided
by Ruas et al. (2012). They
suggest this isoform modu-
lates hypertrophy through
histone modifications near
the promoters of the genes
encoding two potent hyper-
trophic regulators, IGF-1
and myostatin. Specifically,
they propose a model where
PGC-1a4 increases the tran-
scription of IGF-1, an inducer
of muscle growth, and de-
creases transcription of
myostatin, a negative regu-
lator of muscle growth. If
one could design an ideal
molecule as a therapy topromote muscle growth, it would likely
be a potent inducer of IGF-1 while
possessing repressive activity on myo-
statin. In principle, PGC-1a4 may be
that molecule, but much more informa-
tion must be obtained before moving
forward in this regard. For instance,
evaluation of IGF-1 and myostatin pro-
tein levels, in both serum and tissue,
induced by PGC-1a4 are essential, as4 Cell Metabolism 17, January 8, 2013 ª2013the associated gene changes are less
than robust.
In summary, Ruas et al. (2012) identified
a novel isoform of PGC-1a that exerts a
prohypertrophic function (Figure 1). More
work is needed to delineate whether
modulation of PGC-1a4 is an attractive
therapeutic candidate for treatment of
muscle loss in chronic diseases and
aging. These therapies are especiallyElsevier Inc.necessary for those patients
who are not able to exercise
due to their physical condi-
tion. However, for relatively
healthy individuals, it seems
that a simple, old-fashioned
exercise program is still the
best approach to promote
muscle growth.
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